Study is first to explain type of antimalarial drug resistance
November 21, 2013 Editor 0
WASHINGTON — A Georgetown University professor published in the online journal PLOS ONE the first study explaining why drugs designed to fight off malaria stop working in some people with the disease.
Malaria, a mosquito-borne disease caused by a parasite, killed more than 650,000 people in 2010 – most of them children in Africa, according to the World Health Organization.
While several antimalarial drugs have successfully treated the disease, in some regions they no longer work due to drug resistance. Given that just last month the CDC reported that malaria cases in the U.S. reached a 40-year high, this research is particularly timely.
A Global Threat
“Resistance to antimalarial medication threatens the health of more than half of the world’s population,” notes corresponding Paul Roepe, PhD, a Georgetown chemistry professor who authored the study with colleagues at the University of Notre Dame and the University of Kentucky.
Many antimalarial drugs both slow the growth of malarial parasites, and, at higher doses or over longer periods of time, also kill the malarial parasites.
“Until now, no studies have separated how resistance to these two different drug actions might work,” says Roepe, also a professor of biochemistry and cell and molecular biology and co-founder of Georgetown’s Center for Infectious Disease at Georgetown University Medical Center. “Our study found genetic and cell biological evidence linking autophagy to resistance to the parasite, which kills the effects of drugs.”
Autophagy, Roepe explains, is the process by which cells remove damaged parts of themselves to restore normal function. In this case, the cell rids itself of the parts damaged by the antimalarial drug. Roepe worked with two alumni of the chemistry Ph.D. program, David Gaviria (G’13) and Michelle Paguio (G’09), as well as current student Ph.D. chemistry student Amila Siriwardana (G’16) on the research.
The professor and his colleagues demonstrated in their study that while resistance to drugs like chloroquine, which works to slow the growth of malaria, has been explored, an explanation of the resistance to the cell-destroying effects of the medication has not been fully understood.
“These results have important implications in the ongoing development of new antimalarial drug therapy,” Roepe says. “We hope that by publishing this work in an open access journal, more researchers will access it and can expedite drug development.
- Africa: Technology Roadmap Resets Targets On Malaria Vaccines
- Japanese fund to invest in promising technology against malaria, tuberculosis and Chagas disease
- Malaria vaccines: The long war
- New whole plant therapy shows promise as an effective and economical treatment for malaria
- ‘Self-sabotage’ prevents immune protection against malaria
- An innovative system for 3D clinical photography in the resource-limited settings.
Tags: Antimalarial medication, artemisinin, Chloroquine, Health_Medical_Pharma, Malaria
Nigerian VoD content platform Dobox TV offers simultaneous online premiere of cinema releases Open Innovation: One Size Fits All?
Subscribe to our stories
- Entrepreneurial Alertness, Innovation Modes, And Business Models in Small- And Medium-Sized Enterprises December 30, 2021
- The Strategic Role of Design in Driving Digital Innovation June 10, 2021
- Correction to: Hybrid mosquitoes? Evidence from rural Tanzania on how local communities conceptualize and respond to modified mosquitoes as a tool for malaria control June 10, 2021
- BRIEF FOCUS: Optimal spacing for groundnuts in smallholder farming systems June 9, 2021
- COVID-19 pandemic: impacts on the achievements of Sustainable Development Goals in Africa June 9, 2021
Popular Post-All time
- A review on biomass-based... 1k views
- Apply Now: $500,000 for Y... 814 views
- Can blockchain disrupt ge... 809 views
- Test Your Value Propositi... 763 views
- Prize-winning projects pr... 727 views